Revenue growth should surely be returning after that little 2021 slump? Look forward to the Appendix 4C. Commiserations to long-term holders. I appreciate I am only just joining the holders at good levels by comparison. After been invested in many bio-techs with quality products and yet poor financial returns I appreciate the frustration. Still fundamentally a very promising company if they return to those growing revenues out of the grips of COVID.
Revenue growth should surely be returning after that little 2021...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
-0.002(16.7%) |
Mkt cap ! $1.830M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.0¢ | $42.36K | 3.789M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1701089 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 136370 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| OSX (ASX) Chart |